Tolerization of Anti-Galalpha1-3Gal Natural Antibody-forming B Cells by Induction of Mixed Chimerism
Overview
General Medicine
Affiliations
Xenotransplantation could overcome the severe shortage of allogeneic organs, a major factor limiting organ transplantation. Unfortunately, transplantation of organs from pigs, the most suitable potential donor species, results in hyperacute rejection in primate recipients, due to the presence of anti-Galalpha1-3Gal (Gal) natural antibodies (NAbs) in their sera. We evaluated the ability to tolerize anti-Gal NAb-producing B cells in alpha1,3-galactosyltransferase knockout (GalT KO) mice using bone marrow transplantation (BMT) from GalT+/+ wild-type (WT) mice. Lasting mixed chimerism was achieved in KO mice by cotransplantation of GalT KO and WT marrow after lethal irradiation. The levels of anti-Gal NAb in sera of mixed chimeras were reduced markedly 2 wk after BMT, and became undetectable at later time points. Immunization with Gal+/+ xenogeneic cells failed to stimulate anti-Gal antibody production in mixed chimeras, whereas the production of non-Gal-specific antixenoantigen antibodies was stimulated. An absence of anti-Gal-producing B cells was demonstrated by enzyme-linked immunospot assays in mixed KO + WT --> KO chimeras. Thus, mixed chimerism efficiently induces anti-Gal-specific B cell tolerance in addition to T cell tolerance, providing a single approach to overcoming both the humoral and the cellular immune barriers to discordant xenotransplantation.
Physiological basis for xenotransplantation from genetically modified pigs to humans.
Peterson L, Yacoub M, Ayares D, Yamada K, Eisenson D, Griffith B Physiol Rev. 2024; 104(3):1409-1459.
PMID: 38517040 PMC: 11390123. DOI: 10.1152/physrev.00041.2023.
Eisenson D, Hisadome Y, Santillan M, Yamada K Front Transplant. 2024; 1.
PMID: 38390384 PMC: 10883655. DOI: 10.3389/frtra.2022.989811.
Galili U Front Mol Biosci. 2023; 10:1209974.
PMID: 37449060 PMC: 10338101. DOI: 10.3389/fmolb.2023.1209974.
Progress in xenotransplantation: overcoming immune barriers.
Sykes M, Sachs D Nat Rev Nephrol. 2022; 18(12):745-761.
PMID: 36198911 PMC: 9671854. DOI: 10.1038/s41581-022-00624-6.
Eisenson D, Hisadome Y, Yamada K Front Immunol. 2022; 13:899657.
PMID: 35663933 PMC: 9157571. DOI: 10.3389/fimmu.2022.899657.